JPWO2020038379A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020038379A5 JPWO2020038379A5 JP2021509199A JP2021509199A JPWO2020038379A5 JP WO2020038379 A5 JPWO2020038379 A5 JP WO2020038379A5 JP 2021509199 A JP2021509199 A JP 2021509199A JP 2021509199 A JP2021509199 A JP 2021509199A JP WO2020038379 A5 JPWO2020038379 A5 JP WO2020038379A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- antigen
- chain variable
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862720015P | 2018-08-20 | 2018-08-20 | |
| US62/720,015 | 2018-08-20 | ||
| PCT/CN2019/101659 WO2020038379A1 (en) | 2018-08-20 | 2019-08-20 | Novel cancer immunotherapy antibody compositions |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021534750A JP2021534750A (ja) | 2021-12-16 |
| JP2021534750A5 JP2021534750A5 (https=) | 2022-08-22 |
| JPWO2020038379A5 true JPWO2020038379A5 (https=) | 2022-08-22 |
| JP7488534B2 JP7488534B2 (ja) | 2024-05-22 |
Family
ID=69591356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021509199A Active JP7488534B2 (ja) | 2018-08-20 | 2019-08-20 | 新規ながん免疫療法抗体組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12391758B2 (https=) |
| EP (1) | EP3841126A4 (https=) |
| JP (1) | JP7488534B2 (https=) |
| KR (1) | KR20210046725A (https=) |
| CN (2) | CN116410320A (https=) |
| AU (1) | AU2019324388A1 (https=) |
| BR (1) | BR112021003182A2 (https=) |
| CA (1) | CA3110138A1 (https=) |
| MX (1) | MX2021002077A (https=) |
| SG (1) | SG11202101757QA (https=) |
| TW (1) | TW202016150A (https=) |
| WO (1) | WO2020038379A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023187460A1 (en) * | 2022-04-01 | 2023-10-05 | Mabtree Biologics Ag | Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function |
| CN118930652B (zh) * | 2024-07-29 | 2025-03-11 | 北京肿瘤医院(北京大学肿瘤医院) | 一种免疫检查点pd-l2靶向单链抗体及放射性核素标记物与应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104356236B (zh) * | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2615460A1 (en) * | 2005-08-08 | 2007-02-15 | Onconon, Llc | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
| KR101814408B1 (ko) * | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| AU2009333580B2 (en) * | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| NZ628923A (en) * | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| HK1204557A1 (en) | 2012-05-31 | 2015-11-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
| AR093984A1 (es) * | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
| CA2979219A1 (en) | 2015-03-10 | 2016-09-15 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind psma |
| CA2993177A1 (en) | 2015-07-22 | 2017-01-26 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind lag3 |
| CN106432501B (zh) * | 2015-08-06 | 2021-07-30 | 基石药业 | 新型抗pd-l1抗体 |
| WO2017020291A1 (en) * | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| EA037855B1 (ru) * | 2016-01-29 | 2021-05-27 | Сорренто Терапьютикс, Инк. | Полностью человеческое антитело класса igg, связывающееся с эпитопом pd-l1 |
| CN108350082B (zh) * | 2016-06-13 | 2021-09-24 | 天境生物科技(上海)有限公司 | Pd-l1抗体及其用途 |
| CN106496327B (zh) * | 2016-11-18 | 2019-01-15 | 昆山百尔泰生物科技有限公司 | 针对pd-l1胞外段的人源抗体或抗体片段和用途、核苷酸序列和载体 |
| CN108239149B (zh) * | 2016-12-25 | 2021-03-05 | 南京传奇生物科技有限公司 | 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-l1抗体 |
| CN107973854B (zh) * | 2017-12-11 | 2021-05-04 | 苏州银河生物医药有限公司 | Pdl1单克隆抗体及其应用 |
| US12378295B2 (en) * | 2018-10-29 | 2025-08-05 | 1Globe Biomedical Co., Ltd. | Rationally designed protein compositions |
-
2019
- 2019-08-20 US US17/270,034 patent/US12391758B2/en active Active
- 2019-08-20 SG SG11202101757QA patent/SG11202101757QA/en unknown
- 2019-08-20 WO PCT/CN2019/101659 patent/WO2020038379A1/en not_active Ceased
- 2019-08-20 KR KR1020217008130A patent/KR20210046725A/ko not_active Abandoned
- 2019-08-20 BR BR112021003182-0A patent/BR112021003182A2/pt not_active IP Right Cessation
- 2019-08-20 EP EP19853152.7A patent/EP3841126A4/en active Pending
- 2019-08-20 CN CN202310026623.5A patent/CN116410320A/zh active Pending
- 2019-08-20 CA CA3110138A patent/CA3110138A1/en active Pending
- 2019-08-20 JP JP2021509199A patent/JP7488534B2/ja active Active
- 2019-08-20 MX MX2021002077A patent/MX2021002077A/es unknown
- 2019-08-20 TW TW108129705A patent/TW202016150A/zh unknown
- 2019-08-20 CN CN201980054723.0A patent/CN112839963B/zh active Active
- 2019-08-20 AU AU2019324388A patent/AU2019324388A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7547581B2 (ja) | 腫瘍治療薬及びその応用 | |
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| CN111454357B (zh) | 一种含有抗体的肿瘤治疗剂的开发和应用 | |
| JP2021525546A5 (https=) | ||
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2018502050A5 (https=) | ||
| Chen et al. | A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy | |
| JP2020501531A5 (https=) | ||
| FI3820894T3 (fi) | Mesoteliinia ja vastaavasti cd137:ää sitovia molekyylejä | |
| JP2019536430A5 (https=) | ||
| JP2017506067A5 (https=) | ||
| RU2017105915A (ru) | Антитела против pd-1 | |
| WO2022166940A1 (en) | Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors | |
| RU2010129045A (ru) | Связывающие молекулы к рецептору ох40 человека | |
| RU2007145419A (ru) | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами | |
| JP2021524275A5 (https=) | ||
| CN113614111A (zh) | 用于调节细胞内化的组合物和方法 | |
| WO2019196309A1 (zh) | 抗pd-l1抗体及其用途 | |
| JP2021501567A5 (https=) | ||
| JP2021531255A5 (https=) | ||
| CN115605513A (zh) | 一种抗pd-l1和her2的双特异性抗体 | |
| WO2023071676A1 (zh) | 一种抗her2/抗pd-l1双功能抗体及其应用 | |
| JP2021534750A5 (https=) | ||
| JPWO2020038379A5 (https=) | ||
| WO2023163087A1 (ja) | 抗変異ｃａｌｒ抗体と他の薬剤とを組み合わせてなる医薬 |